To maximize Series A runway, biotech investors must look for this key trait
To get to Series B, biotechs must kill dead-end projects fast: prior success + failure predict which shave years of waste
To maintain SaaS growth, sometimes less R&D is actually more
Moderating R&D partnerships adds another 10-20% to share of revenue from new products, crucial for SaaS firms
A little customer focus goes a long way for a biotech being acquired
Early-stage biotechs that put extra effort into customer focus are rewarded with a higher likelihood of being acquired by big pharma
Break room magic - pharma office layout has huge impact on R&D returns
Unlocking hidden value - easy trick for managing creative startups post-acquisition
When digital patent seeking can be the new lifeblood of non-tech industries
Biotech’s that stop doing this to their new product development teams get huge returns
NPD teams meeting too often, or not enough, are inefficient - optimized schedules double profitability of new products.